Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
Date:7/2/2012

WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML).

Under the new agreement, LLS will provide $5 million in funding, through its Therapy Acceleration Program (TAP), for the pivotal, phase 3, multicenter trial of CPX-351 versus conventional cytarabine plus daunorubicin in elderly patients with untreated secondary AML. Celator will provide the balance of funding for the study through its own financing activities.  Enrollment in the study is expected to begin later this year. Should the results confirm that CPX-351 improves overall survival in this patient population, the study will be used to support a New Drug Application (NDA) for CPX-351 in this indication with the U.S. Food and Drug Administration (FDA).

"This is the first time that LLS has provided follow-on funding to a development partner," said Louis DeGennaro, Ph.D., LLS's chief mission officer. "The very promising results of our initial collaboration, as well as Celator's demonstrated ability to pursue its research agenda effectively while working with the FDA to identify an efficient regulatory pathway, give us the confidence to provide an additional $5 million to make CPX-351 available to patients with AML as soon as possible."As part of a 2009 partnership, LLS provided $4.1 million to help fund Celator's Phase 2B multicenter, randomized, open-label trial of CPX-351 versus intensive salvage therapy in adult patients 18-65 years of age with AML in first relapse. The positive results of that trial plus the survival advantage observed in a simi
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
2. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
8. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... PUNE, India , September 4, 2015 /PRNewswire/ ... Industry, 2015 Market Research Report is a professional ... the global Surgical Gown industry with a focus ... will take 2-3 working days once an order ... gown market spread across 150 pages, analyzing and ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)...  Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... on September 10, 2015. DATE: Thursday, September ... http://tinyurl.com/sep10pre This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
Breaking Medicine Technology:Surgical Gown Market 2020 Forecasts With a Focus on China 2Surgical Gown Market 2020 Forecasts With a Focus on China 3Surgical Gown Market 2020 Forecasts With a Focus on China 4Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2
... - Phase 2 trial expected to begin in late ... June 4 Nuvelo, Inc.,(Nasdaq: NUVO ) today ... a,single-center, Phase 1b trial to determine the safety, tolerability ... direct,thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers., ...
... at American Society of Clinical Oncology meeting indicate ... compared to historical data., PRINCETON, N.J., June ... CPX-1 Phase 2 clinical trial in patients,with advanced ... and floxuridine, based on the company,s proprietary,CombiPlex(TM) technology. ...
Cached Medicine Technology:Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 2Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172 3Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 2Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer 3
(Date:9/4/2015)... ... 2015 , ... A Union County charitable organization will host ... is a non-profit organization dedicated to offering Pilates scholarships to cancer patients to ... recover their mobility, strength, and range of motion following breast cancer surgery. ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily stressors and distractions ... and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons ... the island’s only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel ...
(Date:9/4/2015)... , ... September 04, 2015 , ... The USC Eye ... ranked number 9 nationwide by Doximity. Faculty, residents and staff are honored to ... pride in the quality of our ophthalmology residency program. Our faculty places a high ...
(Date:9/4/2015)... New York, NY (PRWEB) , ... September 04, 2015 , ... ... 400 meters qualifying heat, and followed up with victory in the men’s 400 meters ... Caribbean (NACAC) Senior Track and Field Championships in San Jose, Costa Rica in August ...
(Date:9/4/2015)... ... 04, 2015 , ... FiltersFast.com, the online retail leader in ... passed up. FiltersFast.com, will ship all orders over $50.00 for free. Use ... Take advantage of this promotion now through September 8, 2015. , Filtersfast.com offers ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2
... HealthDay Reporter , TUESDAY, Feb. 28 (HealthDay News) ... emergency room with fevers are making the right decision, ... not be generalized, and therefore not approached, as a ... Dr. Yvette van Ierland, from the department of pediatrics ...
... News) -- Exposure to bisphenol A (BPA), a controversial chemical ... developing heart disease later in life, a new study suggests. ... foods and drinks, but also may be exposed through drinking ... 10-year period, researchers compared BPA levels in 758 people who ...
... Researchers at Moffitt Cancer Center in Tampa, Fla., ... inhibitor can prevent resistance to the chemotherapy drug vemurafenib, ... resistance is characterized by a diminished apoptosis (programmed cancer ... between apoptosis and cell survival is regulated by a ...
... elderly cancer patients are evolving as more of the population ... To address these issues and others, national thought leaders ... the Kimmel Cancer Center at Jefferson (KCC) in ... an overview of the latest advances in the understanding and ...
... , TUESDAY, Feb. 28 (HealthDay News) -- Menstrual cramps are the ... of vitamin D may one day be added to the meager ... small study in Italy found that a single, high dose of ... a marked reduction in menstrual cramps, with the largest benefits observed ...
... -- A new influenza A virus has been discovered in Guatemalan ... Control and Prevention. Although the bat flu does not ... more research is needed to determine if the virus could be ... time an influenza virus has been identified in bats, but in ...
Cached Medicine News:Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 2Health News:Parents Often Right to Bring Kids With Fever to the ER: Study 3Health News:BPA Exposure May Raise Risk of Heart Disease 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 3Health News:Vitamin D3 Might Ease Menstrual Cramps 2Health News:Vitamin D3 Might Ease Menstrual Cramps 3Health News:New Flu Discovered in Guatemalan Fruit Bats 2
... a unique and versatile posterior spinal implant ... as a translational implant in correction of ... for bone or metallic implants, cables have ... configurations. Songer Cables offer advantages in strength, ...
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%....
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
... matrix and conductive cancellous chips. ... be free of foreign matter. ... is 125 to 1000 . ... 1 - 8 mm. 5:3 ...
Medicine Products: